AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Robert I. Haddad

Employment: Dana-Farber Cancer Institute

Leadership: NCCN

Consulting or Advisory Role: Celgene, Merck, Eisai, Bristol Myers Squibb, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics, GlaxoSmithKline, Gilead Sciences, Vaccinex, EMD Serono, BioNTech, Achilles Therapeutics, Bayer, Coherus Biosciences, Boehringer Ingelheim, Mirati Therapeutics

Research Funding: Boehringer Ingelheim (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), AstraZeneca (Inst), Genentech (Inst), Pfizer (Inst), Kura Oncology (Inst)

Patents, Royalties, Other Intellectual Property: UpToDate

Other Relationship: Nanobiotix, ISA Pharmaceuticals

Kevin Harrington

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Arch Oncology (Inst), AstraZeneca (Inst), BMS (Inst), Boehringer Ingelheim (Inst), Merck Serono (Inst), MSD (Inst), Oncolys BioPharma (Inst), Pfizer (Inst), Replimune (Inst), Inzen Therapeutics (Inst), Codiak Biosciences (Inst), Scenic Biotech

Consulting or Advisory Role: Arch Oncology (Inst), AstraZeneca (Inst), BMS (Inst), Boehringer Ingelheim (Inst), Merck Serono (Inst), MSD (Inst), Oncolys BioPharma (Inst), Replimune (Inst), Inzen Therapeutics (Inst)

Speakers' Bureau: BMS (Inst), Merck Serono (Inst), MSD (Inst)

Research Funding: AstraZeneca (Inst), Replimune (Inst), Boehringer Ingelheim (Inst)

Makoto Tahara

Honoraria: Bristol Myers Squibb, Eisai, Ono Pharmaceutical, MSD, Lilly, Bayer, Merck Serono

Consulting or Advisory Role: Ono Pharmaceutical, MSD, Pfizer, Bristol Myers Squibb, Rakuten Medical, Bayer, Lilly, Eisai, Boehringer Ingelheim, Genmab, Nektar, Janssen, Nanobiotix, Astellas Pharma

Research Funding: Merck Sharp & Dohme (Inst), AstraZeneca (Inst), Ono Pharmaceutical (Inst), Novartis (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst), Rakuten Medical (Inst), Bayer (Inst), GlaxoSmithKline (Inst), Lilly (Inst), Merck Serono (Inst)

Robert L. Ferris

Stock and Other Ownership Interests: Novasenta

Consulting or Advisory Role: Merck, Pfizer, Numab, Macrogenics, Novasenta, Sanofi, Zymeworks, Bristol Myers Squibb, Aduro Biotech, Achilles Therapeutics, Bicara Therapeutics, Everest Clinical Research, F. Hoffmann LaRoche, Genocea Biosciences, Hookipa Pharma, Instil Bio, Kowa Research Institute, Lifescience Dynamics, Mirati Therapeutics, OncoCyte, PPD, Rakuten Medical, Seattle Genetics, VIR Biotechnology, MeiraGTx, LLC, Adagene Incorporated, Brooklyn Immunotherapeutics LLC, Cantenion, Coherus BioSciences Inc, Mirror Biologics Inc, Nanabiotix, Novartis, SIRPant Immunotherapies

Research Funding: Bristol Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, Novasenta

Maura Gillison

This author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Bristol Myers Squibb, Merck, EMD Serono, BioNTech, Shattuck Labs, Bayer, Debiopharm Group, Ipsen, Gilead Sciences, Bicara Therapeutics, Nektar, Istari, LLX Solutions, OncLive, Seattle Genetics, Kura Oncology, Mirati Therapeutics, Sensei Biotherapeutics, Eisai

Research Funding: Bristol Myers Squibb (Inst), Genocea Biosciences (Inst), Cullinan Oncology (Inst), Genentech (Inst), Agenus (Inst), Kura Oncology (Inst)

Jerome Fayette

Honoraria: AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Innate Pharma, Roche

Consulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Innate Pharma, Roche

Research Funding: Bristol Myers Squibb (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme

Amaury Daste

Consulting or Advisory Role: Merck, MSD, BMS

Travel, Accommodations, Expenses: BMS, Merck

Bogdan Zurawski

Honoraria: BMS, MSD, Merck, GSK, Janssen, Astellas, Exelixis, Syneos, Roche, AstraZeneca

Research Funding: BMS, MSD, Merck, GSK, Janssen, Astellas, Exelixis, Syneos, Roche, AstraZeneca

Expert Testimony: Janssen, Exelixis, BMS, MSD, Merck, GSK, Astellas

Miren Taberna

Employment: Savana

Leadership: Savana

Consulting or Advisory Role: Nanobiotix, Merck, MSD Oncology

Speakers' Bureau: Merck, AstraZeneca Spain, Bristol Myers Squibb, MSD Oncology

Travel, Accommodations, Expenses: AstraZeneca Spain, Merck, MSD Oncology

Nabil F. Saba

Honoraria: Merck, CUE Biopharma, BioNTech, EMD Serono, AstraZeneca, ReachMD, vaccinex, WebMD, Medscape, Clinical Care Options, Kura Oncology, Aduro Biotech

Consulting or Advisory Role: GlaxoSmithKline, Mirati Therapeutics, Eisai, Philips Electronics

Research Funding: Bristol Myers Squibb, Exelixis

Patents, Royalties, Other Intellectual Property: Uptodate chapter writing and editing, Springer textbook Royalty

Travel, Accommodations, Expenses: Merck, Pfizer, GlaxoSmithKline, Blueprint Medicines

Milena Mak

Honoraria: Bayer, Pfizer, Merck Serono, Takeda, Amgen

Consulting or Advisory Role: AstraZeneca

Andrzej Kawecki

Honoraria: Bristol Myers Squibb/Celgene, MSD, Merck Serono

Consulting or Advisory Role: MSD, Bristol Myers Squibb/Celgene, Merck Serono

Research Funding: Bristol Myers Squibb/Celgene, MSD, GlaxoSmithKline, Merck Serono, Sanofi, Roche, AstraZeneca, Macrogenics

Gustavo Girotto

Honoraria: MSD Oncology

Speakers' Bureau: MSD Oncology, Lilly

Research Funding: MSD Oncology (Inst), BMS Brazil (Inst)

Caroline Even

Consulting or Advisory Role: Innate Pharma, Bristol Myers Squibb, MSD Oncology, Merck Serono

Travel, Accommodations, Expenses: MSD Oncology

Joaquin Gabriel Reinoso Toledo

Employment: BMS

Alexander Guminski

Consulting or Advisory Role: Bristol Myers Squibb, Merck, Pfizer, Regeneron, Sun Pharma, MSD Oncology, Sanofi

Research Funding: Sun Pharma (Inst)

Travel, Accommodations, Expenses: Merck KGaA, Sun Pharma

Urs Müller-Richter

Stock and Other Ownership Interests: BioNTech SE

Consulting or Advisory Role: MSD Oncology, BMS GmbH & Co. KG, Sanofi Aventis GmbH

Speakers' Bureau: BMS GmbH & Co KG, MSD Oncology

Naomi Kiyota

Honoraria: Ono Pharmaceutical, Bristol Myers Squibb Japan, Bayer, Chugai Pharma, Merck Serono, MSD, Eisai, AstraZeneca

Consulting or Advisory Role: Shift Zero, Ono Pharmaceutical, Adlai Nortye

Speakers' Bureau: Ono Pharmaceutical, Bristol Myers Squibb Japan, Merck Serono, Eisai, Bayer, MSD, Chugai Pharma

Research Funding: Ono Pharmaceutical (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), Roche (Inst), Rakuten Medical (Inst), Adlai Nortye (Inst)

Mustimbo Roberts

Employment: Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb

Travel, Accommodations, Expenses: Bristol Myers Squibb

Tariq Aziz Khan

Employment: Bristol Myers Squibb/Celgene

Stock and Other Ownership Interests: Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Bristol Myers Squibb/Celgene

Karen Miller-Moslin

Employment: Bristol Myers Squibb, Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb, Bristol Myers Squibb

Li Wei

Employment: Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb

Athanassios Argiris

Consulting or Advisory Role: Merck Serono, Bristol Myers Squibb

Speakers' Bureau: Merck Serono, Bristol Myers Squibb, Debiopharm Group, AstraZeneca

Research Funding: Genentech/Roche, Bristol Myers Squibb

Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Serono

No other potential conflicts of interest were reported.